Changing glucocorticoid action: 11β-Hydroxysteroid dehydrogenase type 1 in acute and chronic inflammation

Since the discovery of cortisone in the 1940s and its early success in treatment of rheumatoid arthritis, glucocorticoids have remained the mainstay of anti-inflammatory therapies. However, cortisone itself is intrinsically inert. To be effective, it requires conversion to cortisol, the active glucocorticoid, by the enzyme 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1). Despite the identification of 11 beta-HSD in liver in 1953 (which we now know to be 11 beta-HSD1), its physiological role has been little explored until recently. Over the past decade, however, it has become apparent that 11 beta-HSD1 plays an important role in shaping endogenous glucocorticoid action. Acute inflammation is more severe with 11 beta-HSD1-deficiency or inhibition, yet in some inflammatory settings such as obesity or diabetes, 11 beta-HSD1-deficiency/inhibition is beneficial, reducing inflammation. Current evidence suggests both beneficial and detrimental effects may result from 11 beta-HSD1 inhibition in chronic inflammatory disease. Here we review recent evidence pertaining to the role of 11 beta-HSD1 in inflammation. This article is part of a Special Issue entitled 'CSR 2013'. (C) 2013 Elsevier Ltd. All rights reserved.